Complete financial analysis of Entera Bio Ltd. (ENTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entera Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kish Bancorp, Inc. (KISB) Income Statement Analysis – Financial Results
- Chiome Bioscience Inc. (4583.T) Income Statement Analysis – Financial Results
- Doppler S.A. (DOPPLER.AT) Income Statement Analysis – Financial Results
- SemiLEDs Corporation (LEDS) Income Statement Analysis – Financial Results
- Heliogen, Inc. (HLGN-WT) Income Statement Analysis – Financial Results
Entera Bio Ltd. (ENTX)
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 134.00K | 571.00K | 365.00K | 236.00K | 500.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.00K | 101.00K | 373.00K | 209.00K | 210.00K | 0.00 | 43.00K | 35.00K | 28.00K |
| Gross Profit | -56.00K | 33.00K | 198.00K | 156.00K | 26.00K | 500.00K | -43.00K | -35.00K | -28.00K |
| Gross Profit Ratio | 0.00% | 24.63% | 34.68% | 42.74% | 11.02% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.51M | 5.85M | 6.77M | 6.40M | 7.20M | 8.52M | 2.77M | 2.65M | 2.12M |
| General & Administrative | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Other Expenses | 0.00 | -51.00K | -46.00K | 1.24M | 743.00K | 523.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.86M | 13.05M | 12.42M | 11.29M | 11.48M | 11.36M | 11.34M | 5.37M | 3.70M |
| Cost & Expenses | 8.86M | 13.15M | 12.79M | 11.50M | 11.69M | 11.36M | 11.34M | 5.37M | 3.70M |
| Interest Income | 31.00K | 83.00K | 0.00 | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 29.00K | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 56.00K | 64.00K | 53.00K | 63.00K | 238.00K | 54.00K | 43.00K | 35.00K | 28.00K |
| EBITDA | -8.80M | -12.87M | -12.16M | -11.11M | -11.35M | -10.81M | -11.05M | -5.33M | -3.67M |
| EBITDA Ratio | 0.00% | -9,714.18% | -2,130.30% | -3,050.14% | -4,752.54% | -2,161.40% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -13.02M | -12.22M | -11.13M | -11.45M | -10.86M | 11.34M | -5.37M | -3.70M |
| Operating Income Ratio | 0.00% | -9,714.18% | -2,139.58% | -3,050.14% | -4,853.39% | -2,172.20% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.00K | 134.00K | -29.00K | -28.00K | 659.00K | 557.00K | 146.00K | 4.17M | -581.00K |
| Income Before Tax | -8.86M | -12.93M | -12.25M | -9.96M | -10.80M | -10.30M | -11.20M | -1.20M | -4.28M |
| Income Before Tax Ratio | 0.00% | -9,652.24% | -2,144.66% | -2,729.59% | -4,574.15% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 29.00K | 137.00K | -59.00K | 20.00K | 84.00K | 557.00K | -146.00K | 0.00 | 0.00 |
| Net Income | -8.89M | -13.07M | -12.19M | -9.98M | -10.88M | -10.30M | -11.20M | -1.20M | -4.28M |
| Net Income Ratio | 0.00% | -9,754.48% | -2,134.33% | -2,735.07% | -4,609.75% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.30 | -1.31 | -0.14 | -0.36 |
| EPS Diluted | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| Weighted Avg Shares Out | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.96M | 8.57M | 8.57M | 11.90M |
| Weighted Avg Shares Out (Dil) | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.98M | 11.90M | 11.90M | 11.90M |
Entera Bio (ENTX) is Overbought: Is A Drop Coming?
Entera Bio (ENTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates
‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors
BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking...
Entera Appoints Ramesh Ratan as Chief Financial Officer
BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S....
New Data Suggest Entera's Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress
BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled “Pharmacokinetics of an Oral Human...
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2020 Results - Earnings Call Transcript
Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2020 Results - Earnings Call Transcript
ENTX Stock Price Increased 70.79%: Why It Happened
The stock price of Entera Bio Ltd (NASDAQ: ENTX) increased by 70.79% yesterday. This is why it happened.
Halted Stocks: What to Know as ENTX Stock Faces Trading Halts
ENTX stock continues to sky rocket, leading investors to question halted stocks. Here's what you should know now.
ENTX Stock Price Increases Over 40% Pre-Market: Why It Happened
The stock price of Entera Bio Ltd (Nasdaq: ENTX) has increased by over 40% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports